Latest Hiv Testing News

Page 1 of 1
Atomo Diagnostics has landed a significant $630,000 order to supply HIV self-tests for a federally funded Australian health initiative, reinforcing its role in expanding accessible testing.
Ada Torres
Ada Torres
6 Feb 2026
A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
Logan Eniac
31 Jan 2026
Atomo Diagnostics has secured a substantial A$416,000 order for its HIV Self-Test kits destined for an African country, marking its second Global Fund-backed contract this year and signalling growing global demand.
Ada Torres
Ada Torres
30 Jan 2026
Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.
Ada Torres
Ada Torres
28 Jan 2026
Atomo Diagnostics has landed a significant $502,000 order for HIV self-tests destined for an African country, underscoring sustained demand for accessible diagnostics in the region.
Ada Torres
Ada Torres
15 Jan 2026
Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.
Ada Torres
Ada Torres
29 Oct 2025
Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.
Ada Torres
Ada Torres
29 July 2025
Atomo Diagnostics has landed a significant $450,000 order to supply HIV self-tests for a federally funded Australian program aimed at increasing at-home testing among high-risk groups.
Ada Torres
Ada Torres
27 May 2025
Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.
Ada Torres
Ada Torres
30 Jan 2025